Oncologist Dr. Eugenio Galindo provides a professional look at a brand new advanced breast cancer drug, recently trialed in Texas.
A revolutionary new drug, recently tested in Texas, could provide help to tens of thousands of women living with advanced breast cancer, according to Dr. Eugenio Galindo. Touted to support the management of the disease, without reliance on painful, traditional treatments, such as intravenous chemotherapy, the oncology specialist provides a closer look at the recently trialed drug, known as alpelisib.
The drug, alpelisib, branded Piqray by pharmaceutical company Novartis, was approved by the U.S. Food and Drug Administration at the end of May. “Piqray has already demonstrated success in clinical trials, conducted, in part, here in the state of Texas,” explains Dr. Galindo, a prominent oncologist serving the Rio Grande Valley area of South Texas for almost 30 years.
According to the specialist, certain patients diagnosed with metastatic hormone receptor-positive breast cancer are likely eligible for treatment with the new drug. “It does remain, however, that only a specific subset of cancer patients, with PIK3CA gene mutation, are suitable,” adds Dr. Galindo, “yet this still represents many, many thousands of women who are diagnosed every year in the United States.”
Alpelisib is claimed by Novartis, as Piqray, to help manage advanced breast cancer. “The drug is designed to stop tumor growth,” Dr. Galindo explains, “allowing patients to live normal lives, without having to endure traditional and encumbering therapies, such as intravenous chemotherapy.”
Cancer treatments, he suggests, are, in general, moving in this direction. “Newer drugs, such as alpelisib, are targeted to specific tumor traits on a molecular level,” reveals the expert.
Combined with hormone therapy, recent Piqray trials carried out in Texas and elsewhere in the U.S. are reported by Novartis to demonstrate, potentially, almost doubled progression-free survival. “Furthermore, upwards of one-third of patients who partook in the trial witnessed their tumors shrink,” adds Dr. Galindo, “and, in some cases, disappear, according to Novartis.”
Novartis, or Novartis International AG, is a multinational pharmaceutical company based in Basel, Switzerland, and one of the world’s largest pharmaceutical companies by market capitalization and sales. Novartis is a member of the European Federation of Pharmaceutical Industries and Associations, the International Federation of Pharmaceutical Manufacturers and Associations, and Pharmaceutical Research and Manufacturers of America.
“Early results, as they pertain to alpelisib, or Piqray, are incredibly positive,” Dr. Galindo suggests, wrapping up, “which provides great hope for those diagnosed with various forms of breast cancer, today and in the future, and further demonstrates the critical importance of ongoing cancer research, both here in Texas and across America, as well as globally.”
Dr. Eugenio Galindo is an experienced physician specializing in oncology, certified through the American Board of Internal Medicine. Dr. Galindo has served in the Rio Grande Valley area for almost three decades and is an active participant in bringing the latest in cancer treatment and screening to the southernmost tip of South Texas. Fluent in English and Spanish, Dr. Galindo has also authored several influential medical publications on the subject of oncology.